Research Article: Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses?

Date Published: June 30, 2009

Publisher: Public Library of Science

Author(s): David K. Shay, Benjamin J. Ridenhour

Abstract: David K. Shay and Benjamin Ridenhour discuss a modeling study predicting that stockpiling a secondary antiviral for use early in a flu pandemic can forestall resistance to the primary stockpiled drug.

Partial Text: In the May 2009 issue of PLoS Medicine, Wu and colleagues presented the results of a series of mathematical models that examine how the use of influenza antiviral drugs might influence the development of antiviral resistance [1]. Their analyses suggest that a small supplemental stockpile of an alternative antiviral, in addition to a primary stockpiled antiviral (oseltamivir for every country that has stockpiled antivirals to date), could reduce levels of resistance to the primary drug during the early phases of an influenza pandemic. The recent emergence and spread of a novel influenza A(H1N1) virus in North America makes these results timely and potentially important to the world’s response to this virus [2]. Can we use the study by Wu et al. to inform current public policy development to respond to this pandemic threat?



Leave a Reply

Your email address will not be published.